---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-208282"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:19:23.003487+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath reports positive results from two independent studies on CHEMOSAT and HEPZATO KIT in liver cancers

## Summary
- CHEMOSAT study: 91% disease control rate, 18.2% complete response in liver tumors; median hepatic PFS 52 weeks overall.
- CHEMOSAT in uveal melanoma: median hepatic PFS 69 weeks; in cholangiocarcinoma: 38 weeks.
- HEPZATO KIT first-line: median OS 22.4 months, hepatic PFS 17.6 months vs 8.8 months for immunotherapy.
- HEPZATO KIT second-line: median PFS 22.2 months; hepatic PFS not reached vs 14.7 months for immunotherapy.
- Both studies published in peer-reviewed journals (ESMO GI and Annals of Surgical Oncology).

## SEC filing metadata
- accession: 0001193125-24-208282
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312524208282/0001193125-24-208282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312524208282/d848260d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-208282
- JSON: https://secwatch.observer/filing/0001193125-24-208282.json
- Plain text: https://secwatch.observer/filing/0001193125-24-208282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.